Suppressive effect of isofraxidin on the overexpression of IL-6 and its molecular mechanism in a TPA-treated human hepatocellular carcinoma cell line, HuH-7
Naunyn-Schmiedeberg's Archives of Pharmacology · 2025
DOI: 10.1007/s00210-024-03394-z ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Taisuke Yamazaki und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Cell Biology, Kohno Clinical Medicine Research Institute, 3-4-4 Kita-Shinagawa, Shinagawa-Ku, 140-0001, Tokyo, Japan. t.yamazaki@…. Hauptthemen laut MEDLINE: Interleukin-6, Carcinoma, Hepatocellular, Liver Neoplasms, Coumarins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
Interleukin-6 (IL-6) is a pleiotropic cytokine that has many biological activities, including inflammation, hematopoiesis, bone metabolism, embryonic development, and other fundamental processes. Recently, IL-6 has been widely recognized as an important pro-inflammatory cytokine involved in cytokine storm pathogenesis during severe inflammatory diseases, such as coronavirus disease 2019 (COVID-19). Therefore, IL-6 is considered to be a therapeutic target for inhibiting cytokine storm. In the present study, we investigated the suppressive effect of isofraxidin, a major coumarin compound of Acanthopanax senticosus, on the overexpression of IL-6 and its molecular mechanism. The expression of IL-6 mRNA was measured using quantitative real-time PCR, and intracellular signaling molecules were detected using western blotting. When the HuH-7 human hepatocellular carcinoma cell line and HepG2 human hepatoblastoma cell line were treated with 12-O-tetradecanoylphorbol 13-acetate (TPA), a marked induction of IL-6 mRNA expression was observed in HuH-7 cells compared with HepG2 cells. Isofraxidin significantly suppressed TPA-induced IL-6 mRNA expression in HuH-7 cells in a dose-dependent manner. Furthermore, isofraxidin inhibited TPA-induced phosphorylation of ERK1/2 in a dose-dependent manner. Similarly, the MAPK/ERK inhibitor U0126 suppressed TPA-induced IL-6 mRNA expression. However, isofraxidin had no effects on TPA-induced phosphorylation of SAPK/JNK, Akt (Ser473), and STAT3 (Tyr705), nuclear translocation of NF-κB p65, and degradation of IκB. Taken together, isofraxidin suppresses TPA-induced overexpression of IL-6 mRNA by selectively inhibiting the activation of the MAPK/ERK pathway in HuH-7 cells, indicating that isofraxidin may be an effective anti-inflammatory agent for treating cytokine storm.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Liver Cell Biology, Kohno Clinical Medicine Research Institute, 3-4-4 Kita-Shinagawa, Shinagawa-Ku, 140-0001, Tokyo, Japan. t.yamazaki@kcmi.or.jp.
- Department of Liver Cell Biology, Kohno Clinical Medicine Research Institute, 3-4-4 Kita-Shinagawa, Shinagawa-Ku, 140-0001, Tokyo, Japan.
Zitieren
APA
Yamazaki, T., & Tokiwa, T. (2025). Suppressive effect of isofraxidin on the overexpression of IL-6 and its molecular mechanism in a TPA-treated human hepatocellular carcinoma cell line, HuH-7. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-024-03394-z
Vancouver
Yamazaki T, Tokiwa T. Suppressive effect of isofraxidin on the overexpression of IL-6 and its molecular mechanism in a TPA-treated human hepatocellular carcinoma cell line, HuH-7. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-024-03394-z
BibTeX
@article{Yamazaki2025,
author = {Yamazaki, Taisuke and Tokiwa, Takayoshi},
title = {Suppressive effect of isofraxidin on the overexpression of IL-6 and its molecular mechanism in a TPA-treated human hepatocellular carcinoma cell line, HuH-7},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2025},
doi = {10.1007/s00210-024-03394-z}
}
EUVIMED